Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Body mass index
Epidermal growth factor mutation
Intramuscular adipose tissue content
Non-small cell lung cancer
Psoas muscle index
Sarcopenia
Tyrosine kinase inhibitor
Visceral-to-subcutaneous fat ratio
Journal
World journal of oncology
ISSN: 1920-454X
Titre abrégé: World J Oncol
Pays: Canada
ID NLM: 101564097
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
16
11
2019
accepted:
02
12
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
ppublish
Résumé
Sarcopenia and obesity have been suspected as factors associated with efficacy of treatment and prognosis in various malignancies. This study aimed to investigate the association of pretreatment sarcopenia and visceral obesity with efficacy and prognosis of first- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for patients with non-small cell lung cancer (NSCLC) and positive EGFR mutation. We retrospectively collected 167 NSCLC patients with mutant EGFR who had started EGFR-TKI monotherapy between October 2007 and August 2018 at our hospital. We classified 167 patients into two groups, according to the definition of underweight based on the World Health Organization (WHO) body mass index (BMI) classification and the Japanese sex-specific cut-off values of the following computed tomography (CT) images-assessed markers of pretreatment sarcopenia or visceral obesity, such as psoas muscle index (PMI), intramuscular adipose tissue content (IMAC) and visceral-to-subcutaneous fat ratio (VSR) at lumbar vertebra L3 level. We compared overall survival (OS) and progression-free survival (PFS) of two groups by Kaplan-Meier curves and log-rank tests. Using multivariate Cox proportional hazard analyses adjusted by age, neutrophil-to-lymphocyte ratio, performance status, EGFR mutation types and EGFR-TKI lines, and extra-pulmonary metastases or three or more than 3 metastatic sites, we searched independent prognostic factors of OS and PFS of EGFR-TKI therapy. The OS (median 26.0 vs. 32.3 months, P = 0.02) and PFS (9.1 vs. 14.8 months, P = 0.03) of patients with BMI < 18.5 were significantly shorter than those of patients with BMI ≥ 18.5. However, there was no significant difference in OS and PFS according to PMI, IMAC and VSR. The multivariate analyses detected only BMI < 18.5 as an unfavorable prognostic factor of shorter OS (hazard ratio (HR) 1.70, 95% confidence interval (CI) 1.03 - 2.81, P = 0.04) and PFS (HR 1.72, 95% CI 1.11 - 2.67, P = 0.02). Pretreatment underweight was a significant prognostic factor of poor PFS and OS of EGFR-TKI therapy. However, neither pretreatment sarcopenia nor visceral obesity was associated with prognosis of EGFR-TKI. Underweight may be a surrogate for advanced disease burden.
Sections du résumé
BACKGROUND
BACKGROUND
Sarcopenia and obesity have been suspected as factors associated with efficacy of treatment and prognosis in various malignancies. This study aimed to investigate the association of pretreatment sarcopenia and visceral obesity with efficacy and prognosis of first- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for patients with non-small cell lung cancer (NSCLC) and positive EGFR mutation.
METHODS
METHODS
We retrospectively collected 167 NSCLC patients with mutant EGFR who had started EGFR-TKI monotherapy between October 2007 and August 2018 at our hospital. We classified 167 patients into two groups, according to the definition of underweight based on the World Health Organization (WHO) body mass index (BMI) classification and the Japanese sex-specific cut-off values of the following computed tomography (CT) images-assessed markers of pretreatment sarcopenia or visceral obesity, such as psoas muscle index (PMI), intramuscular adipose tissue content (IMAC) and visceral-to-subcutaneous fat ratio (VSR) at lumbar vertebra L3 level. We compared overall survival (OS) and progression-free survival (PFS) of two groups by Kaplan-Meier curves and log-rank tests. Using multivariate Cox proportional hazard analyses adjusted by age, neutrophil-to-lymphocyte ratio, performance status, EGFR mutation types and EGFR-TKI lines, and extra-pulmonary metastases or three or more than 3 metastatic sites, we searched independent prognostic factors of OS and PFS of EGFR-TKI therapy.
RESULTS
RESULTS
The OS (median 26.0 vs. 32.3 months, P = 0.02) and PFS (9.1 vs. 14.8 months, P = 0.03) of patients with BMI < 18.5 were significantly shorter than those of patients with BMI ≥ 18.5. However, there was no significant difference in OS and PFS according to PMI, IMAC and VSR. The multivariate analyses detected only BMI < 18.5 as an unfavorable prognostic factor of shorter OS (hazard ratio (HR) 1.70, 95% confidence interval (CI) 1.03 - 2.81, P = 0.04) and PFS (HR 1.72, 95% CI 1.11 - 2.67, P = 0.02).
CONCLUSIONS
CONCLUSIONS
Pretreatment underweight was a significant prognostic factor of poor PFS and OS of EGFR-TKI therapy. However, neither pretreatment sarcopenia nor visceral obesity was associated with prognosis of EGFR-TKI. Underweight may be a surrogate for advanced disease burden.
Identifiants
pubmed: 31921375
doi: 10.14740/wjon1244
pmc: PMC6940038
doi:
Types de publication
Journal Article
Langues
eng
Pagination
187-198Informations de copyright
Copyright 2019, Minami et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interests.
Références
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3353-3356
pubmed: 29286350
J Gastroenterol Hepatol. 2013 Sep;28(9):1507-14
pubmed: 23577962
Medicine (Baltimore). 2018 Jun;97(22):e10988
pubmed: 29851855
J Hepatol. 2015 Jul;63(1):131-40
pubmed: 25724366
Gut. 2010 Mar;59(3):341-7
pubmed: 19837679
Eur J Cancer Care (Engl). 2017 Nov;26(6):null
pubmed: 28488812
Korean J Intern Med. 2016 Nov;31(6):1140-1149
pubmed: 27017943
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Natl Cancer Inst. 2018 Aug 1;110(8):831-842
pubmed: 29518203
Int J Urol. 2015 May;22(5):455-61
pubmed: 25631365
Anticancer Res. 2019 Apr;39(4):1987-1996
pubmed: 30952742
Nutrition. 2016 Nov-Dec;32(11-12):1200-5
pubmed: 27292773
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Transplantation. 2017 Mar;101(3):565-574
pubmed: 27926595
Cancer. 2006 Aug 15;107(4):781-92
pubmed: 16847887
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):13-16
pubmed: 28069727
Gynecol Oncol. 2014 Apr;133(1):11-5
pubmed: 24680585
Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505
pubmed: 28168310
Thorac Cancer. 2016 Jan;7(1):61-5
pubmed: 26816540
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Thorac Cancer. 2019 Apr;10(4):880-889
pubmed: 30821083
Future Oncol. 2018 Apr;14(10):919-926
pubmed: 29528255
J Am Coll Surg. 2013 Jun;216(6):1070-81
pubmed: 23523147
Eur J Cardiothorac Surg. 2017 Jun 1;51(6):1164-1170
pubmed: 28199511
Langenbecks Arch Surg. 2018 Mar;403(2):245-253
pubmed: 29196841
J Surg Oncol. 2012 Mar 15;105(4):365-70
pubmed: 21751219
J Thorac Oncol. 2019 Sep;14(9):1594-1607
pubmed: 31163278